Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors
Alena Skrahina, Henadz Hurevich, Aksana Zalutskaya, Evgeni Sahalchyk, Andrei Astrauko, Sven Hoffner, Valiantsin Rusovich, Andrei Dadu, Pierpaolo de Colombani, Masoud Dara, Wayne van Gemert & Matteo Zignol
Volume 91, Number 1, January 2013, 36-45
Table 2. Resistance to first-line drugs in Mycobacterium tuberculosis isolates, Belarus, 2010–2011
| Resistance | Isolates from new cases (n = 934) |
Isolates from previously treated cases (n = 410) |
All isolates (n = 1344) |
|||||
|---|---|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | |||
| Any first-line drug | 458 | 49.0 (46.2–51.9) | 335 | 81.7 (78.5–84.5) | 793 | 59.0 (56.7–61.3) | ||
| Isoniazid | 377 | 40.4 (37.6–43.2) | 319 | 77.8 (74.4–80.9) | 696 | 51.8 (49.5–54.1) | ||
| Rifampicin | 307 | 32.9 (30.3–35.6) | 316 | 77.1 (73.7–80.2) | 623 | 46.4 (44.1–48.7) | ||
| MDR-TB | 302 | 32.3 (29.7–35.0) | 310 | 75.6 (72.1–78.8) | 612 | 45.5 (43.2–47.9) | ||
| Ethambutol | 217 | 23.2 (20.9–25.7) | 227 | 55.4 (51.5–59.2) | 444 | 33.0 (30.9–35.3) | ||
| Streptomycin | 421 | 45.1 (42.3–47.9) | 329 | 80.2 (77.0–83.1) | 750 | 55.8 (53.5–58.1) | ||
CI, confidence interval; MDR-TB, multidrug-resistant tuberculosis.